NCT07337447
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07337447
Title Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01) (REWENEC 01)
Acronym REWENEC 01
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hospices Civils de Lyon
Indications
Therapies
Age Groups: senior
Covered Countries FRA

Facility Status City State Zip Country Details
CHU Amiens Picardie Amiens France Details
CHU Avicenne APHP Bobigny France Details
CHU Caen Normandie Caen France Details
Hôpital Beaujon Clichy France Details
Hôpital Henri MONDOR Créteil France Details
CHU Dijon Dijon France Details
CHU de Grenoble Grenoble France Details
Centre Oscar Lambret Lille France Details
Service d'Oncologie Médicale - Hôpital Edouard Herriot - Hospices Civils de Lyon Lyon France Details
CHU Timone Marseille France Details
Institut Paoli Calmettes Marseille France Details
CHU Montpellier - Hôpital Saint Eloi Montpellier France Details
HEGP Paris France Details
Hôpital Saint Antoine APHP Paris France Details
Hôpital Saint Louis APHP Paris France Details
CHU de Bordeaux - Hôpital Haut-Leveque Pessac France Details
CHU de Poitiers Poitiers France Details
Hôpital Robert Debré, CHU de Reims Reims France Details
CHU Rouen Rouen France Details
Centre Paul Strauss Strasbourg France Details
Institut Gustave Roussy Villejuif France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field